Equities

Immunitybio Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Immunitybio Inc

Actions
  • Price (EUR)7.20
  • Today's Change0.116 / 1.64%
  • Shares traded500.00
  • 1 Year change+109.25%
  • Beta-0.1349
Data delayed at least 15 minutes, as of Feb 20 2026 12:05 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2024202420232022
ASSETS
Cash And Short Term Investments150266107
Total Receivables, Net2.653.171.89
Total Inventory8.27----
Prepaid expenses212026
Other current assets, total2.364.135.15
Total current assets185294141
Property, plant & equipment, net170183190
Goodwill, net0.91----
Intangibles, net151720
Long term investments00.890.84
Note receivable - long term7.136.886.63
Other long term assets4.342.824.73
Total assets383504362
LIABILITIES
Accounts payable6.739.2021
Accrued expenses474643
Notes payable/short-term debt00432
Current portion long-term debt/capital leases1.251.481.42
Other current liabilities, total0.171.143.47
Total current liabilities5558501
Total long term debt746837241
Total debt748838675
Deferred income tax------
Minority interest0.971.05(2.49)
Other liabilities, total7019570
Total liabilities8721,091810
SHAREHOLDERS EQUITY
Common stock0.090.070.04
Additional paid-in capital2,8852,3751,931
Retained earnings (accumulated deficit)(3375)(2962)(2378)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total1.200.010.18
Total equity(489)(587)(447)
Total liabilities & shareholders' equity383504362
Total common shares outstanding853671422
Treasury shares - common primary issue0.160.160.16
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.